IBDEI02Q ; ; 13-FEB-2014
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 13, 2014
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,3133,2)
 ;;=^267532
 ;;^UTILITY(U,$J,358.3,3134,0)
 ;;=205.10^^29^257^18
 ;;^UTILITY(U,$J,358.3,3134,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,3134,1,1,0)
 ;;=1^205.10
 ;;^UTILITY(U,$J,358.3,3134,1,8,0)
 ;;=8^Chr Myeloid Leukemia w/o Remission
 ;;^UTILITY(U,$J,358.3,3134,2)
 ;;=^267533
 ;;^UTILITY(U,$J,358.3,3135,0)
 ;;=205.11^^29^257^17
 ;;^UTILITY(U,$J,358.3,3135,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,3135,1,1,0)
 ;;=1^205.11
 ;;^UTILITY(U,$J,358.3,3135,1,8,0)
 ;;=8^Chr Myeloid Leukemia in Remission
 ;;^UTILITY(U,$J,358.3,3135,2)
 ;;=^267534
 ;;^UTILITY(U,$J,358.3,3136,0)
 ;;=289.0^^29^257^50
 ;;^UTILITY(U,$J,358.3,3136,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,3136,1,1,0)
 ;;=1^289.0
 ;;^UTILITY(U,$J,358.3,3136,1,8,0)
 ;;=8^Secondary Polycythemia
 ;;^UTILITY(U,$J,358.3,3136,2)
 ;;=^186856
 ;;^UTILITY(U,$J,358.3,3137,0)
 ;;=238.4^^29^257^48
 ;;^UTILITY(U,$J,358.3,3137,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,3137,1,1,0)
 ;;=1^238.4
 ;;^UTILITY(U,$J,358.3,3137,1,8,0)
 ;;=8^Polycythemia Rubra Vera
 ;;^UTILITY(U,$J,358.3,3137,2)
 ;;=^96105
 ;;^UTILITY(U,$J,358.3,3138,0)
 ;;=288.9^^29^257^67
 ;;^UTILITY(U,$J,358.3,3138,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,3138,1,1,0)
 ;;=1^288.9
 ;;^UTILITY(U,$J,358.3,3138,1,8,0)
 ;;=8^Unspecified Dis Of W B C
 ;;^UTILITY(U,$J,358.3,3138,2)
 ;;=^267993
 ;;^UTILITY(U,$J,358.3,3139,0)
 ;;=289.81^^29^257^49
 ;;^UTILITY(U,$J,358.3,3139,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,3139,1,1,0)
 ;;=1^289.81
 ;;^UTILITY(U,$J,358.3,3139,1,8,0)
 ;;=8^Primary Hypercoagulable State
 ;;^UTILITY(U,$J,358.3,3139,2)
 ;;=^329886
 ;;^UTILITY(U,$J,358.3,3140,0)
 ;;=238.75^^29^257^29
 ;;^UTILITY(U,$J,358.3,3140,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,3140,1,1,0)
 ;;=1^238.75
 ;;^UTILITY(U,$J,358.3,3140,1,8,0)
 ;;=8^Myelodysplastic Syndrome
 ;;^UTILITY(U,$J,358.3,3140,2)
 ;;=^334031
 ;;^UTILITY(U,$J,358.3,3141,0)
 ;;=289.9^^29^257^66
 ;;^UTILITY(U,$J,358.3,3141,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,3141,1,1,0)
 ;;=1^289.9
 ;;^UTILITY(U,$J,358.3,3141,1,8,0)
 ;;=8^Unspecified Blood Disease
 ;;^UTILITY(U,$J,358.3,3141,2)
 ;;=^55344
 ;;^UTILITY(U,$J,358.3,3142,0)
 ;;=205.02^^29^257^30
 ;;^UTILITY(U,$J,358.3,3142,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,3142,1,1,0)
 ;;=1^205.02
 ;;^UTILITY(U,$J,358.3,3142,1,8,0)
 ;;=8^Myeloid Leukemia in Relapse
 ;;^UTILITY(U,$J,358.3,3142,2)
 ;;=^336470
 ;;^UTILITY(U,$J,358.3,3143,0)
 ;;=205.12^^29^257^16
 ;;^UTILITY(U,$J,358.3,3143,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,3143,1,1,0)
 ;;=1^205.12
 ;;^UTILITY(U,$J,358.3,3143,1,8,0)
 ;;=8^Chr Myeloid Leukemia in Relapse
 ;;^UTILITY(U,$J,358.3,3143,2)
 ;;=^336471
 ;;^UTILITY(U,$J,358.3,3144,0)
 ;;=205.20^^29^257^59
 ;;^UTILITY(U,$J,358.3,3144,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,3144,1,1,0)
 ;;=1^205.20
 ;;^UTILITY(U,$J,358.3,3144,1,8,0)
 ;;=8^Subacute Myeloid Leuk w/o Remiss
 ;;^UTILITY(U,$J,358.3,3144,2)
 ;;=^336857
 ;;^UTILITY(U,$J,358.3,3145,0)
 ;;=205.21^^29^257^58
 ;;^UTILITY(U,$J,358.3,3145,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,3145,1,1,0)
 ;;=1^205.21
 ;;^UTILITY(U,$J,358.3,3145,1,8,0)
 ;;=8^Subacute Myeloid Leuk in Remiss
 ;;^UTILITY(U,$J,358.3,3145,2)
 ;;=^267536
 ;;^UTILITY(U,$J,358.3,3146,0)
 ;;=205.22^^29^257^57
 ;;^UTILITY(U,$J,358.3,3146,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,3146,1,1,0)
 ;;=1^205.22
 ;;^UTILITY(U,$J,358.3,3146,1,8,0)
 ;;=8^Subacute Myeloid Leuk in Relapse
 ;;^UTILITY(U,$J,358.3,3146,2)
 ;;=^336472
 ;;^UTILITY(U,$J,358.3,3147,0)
 ;;=205.30^^29^257^35
 ;;^UTILITY(U,$J,358.3,3147,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,3147,1,1,0)
 ;;=1^205.30
 ;;^UTILITY(U,$J,358.3,3147,1,8,0)
 ;;=8^Myeloid Sarcoma w/o Remission
 ;;^UTILITY(U,$J,358.3,3147,2)
 ;;=^336858
 ;;^UTILITY(U,$J,358.3,3148,0)
 ;;=205.31^^29^257^34
 ;;^UTILITY(U,$J,358.3,3148,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,3148,1,1,0)
 ;;=1^205.31
 ;;^UTILITY(U,$J,358.3,3148,1,8,0)
 ;;=8^Myeloid Sarcoma in Remission
 ;;^UTILITY(U,$J,358.3,3148,2)
 ;;=^267538
 ;;^UTILITY(U,$J,358.3,3149,0)
 ;;=205.32^^29^257^33
 ;;^UTILITY(U,$J,358.3,3149,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,3149,1,1,0)
 ;;=1^205.32
 ;;^UTILITY(U,$J,358.3,3149,1,8,0)
 ;;=8^Myeloid Sarcoma in Relapse
 ;;^UTILITY(U,$J,358.3,3149,2)
 ;;=^336473
 ;;^UTILITY(U,$J,358.3,3150,0)
 ;;=205.80^^29^257^44
 ;;^UTILITY(U,$J,358.3,3150,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,3150,1,1,0)
 ;;=1^205.80
 ;;^UTILITY(U,$J,358.3,3150,1,8,0)
 ;;=8^Oth Myeloid Leukemia w/o Remission
 ;;^UTILITY(U,$J,358.3,3150,2)
 ;;=^336859
 ;;^UTILITY(U,$J,358.3,3151,0)
 ;;=205.81^^29^257^43
 ;;^UTILITY(U,$J,358.3,3151,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,3151,1,1,0)
 ;;=1^205.81
 ;;^UTILITY(U,$J,358.3,3151,1,8,0)
 ;;=8^Oth Myeloid Leukemia in Remission
 ;;^UTILITY(U,$J,358.3,3151,2)
 ;;=^267540
 ;;^UTILITY(U,$J,358.3,3152,0)
 ;;=205.82^^29^257^42
 ;;^UTILITY(U,$J,358.3,3152,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,3152,1,1,0)
 ;;=1^205.82
 ;;^UTILITY(U,$J,358.3,3152,1,8,0)
 ;;=8^Oth Myeloid Leukemia in Relapse
 ;;^UTILITY(U,$J,358.3,3152,2)
 ;;=^336474
 ;;^UTILITY(U,$J,358.3,3153,0)
 ;;=205.90^^29^257^65
 ;;^UTILITY(U,$J,358.3,3153,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,3153,1,1,0)
 ;;=1^205.90
 ;;^UTILITY(U,$J,358.3,3153,1,8,0)
 ;;=8^Unspec Myeloid Leuk w/o Remission
 ;;^UTILITY(U,$J,358.3,3153,2)
 ;;=^336860
 ;;^UTILITY(U,$J,358.3,3154,0)
 ;;=205.91^^29^257^64
 ;;^UTILITY(U,$J,358.3,3154,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,3154,1,1,0)
 ;;=1^205.91
 ;;^UTILITY(U,$J,358.3,3154,1,8,0)
 ;;=8^Unspec Myeloid Leuk in Remission
 ;;^UTILITY(U,$J,358.3,3154,2)
 ;;=^267542
 ;;^UTILITY(U,$J,358.3,3155,0)
 ;;=205.92^^29^257^63
 ;;^UTILITY(U,$J,358.3,3155,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,3155,1,1,0)
 ;;=1^205.92
 ;;^UTILITY(U,$J,358.3,3155,1,8,0)
 ;;=8^Unspec Myeloid Leuk in Relapse
 ;;^UTILITY(U,$J,358.3,3155,2)
 ;;=^336475
 ;;^UTILITY(U,$J,358.3,3156,0)
 ;;=206.00^^29^257^6
 ;;^UTILITY(U,$J,358.3,3156,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,3156,1,1,0)
 ;;=1^206.00
 ;;^UTILITY(U,$J,358.3,3156,1,8,0)
 ;;=8^Acute Monocytic Leuk w/o Remission
 ;;^UTILITY(U,$J,358.3,3156,2)
 ;;=^336861
 ;;^UTILITY(U,$J,358.3,3157,0)
 ;;=206.01^^29^257^5
 ;;^UTILITY(U,$J,358.3,3157,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,3157,1,1,0)
 ;;=1^206.01
 ;;^UTILITY(U,$J,358.3,3157,1,8,0)
 ;;=8^Acute Monocytic Leuk in Remission
 ;;^UTILITY(U,$J,358.3,3157,2)
 ;;=^267544
 ;;^UTILITY(U,$J,358.3,3158,0)
 ;;=206.02^^29^257^4
 ;;^UTILITY(U,$J,358.3,3158,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,3158,1,1,0)
 ;;=1^206.02
 ;;^UTILITY(U,$J,358.3,3158,1,8,0)
 ;;=8^Acute Monocytic Leuk in Relapse
 ;;^UTILITY(U,$J,358.3,3158,2)
 ;;=^336476
 ;;^UTILITY(U,$J,358.3,3159,0)
 ;;=206.10^^29^257^15
 ;;^UTILITY(U,$J,358.3,3159,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,3159,1,1,0)
 ;;=1^206.10
 ;;^UTILITY(U,$J,358.3,3159,1,8,0)
 ;;=8^Chr Monocytic Leuk w/o Remission
 ;;^UTILITY(U,$J,358.3,3159,2)
 ;;=^336862
 ;;^UTILITY(U,$J,358.3,3160,0)
 ;;=206.11^^29^257^14
 ;;^UTILITY(U,$J,358.3,3160,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,3160,1,1,0)
 ;;=1^206.11
 ;;^UTILITY(U,$J,358.3,3160,1,8,0)
 ;;=8^Chr Monocytic Leuk in Remission
 ;;^UTILITY(U,$J,358.3,3160,2)
 ;;=^267546
 ;;^UTILITY(U,$J,358.3,3161,0)
 ;;=206.12^^29^257^13
 ;;^UTILITY(U,$J,358.3,3161,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,3161,1,1,0)
 ;;=1^206.12
 ;;^UTILITY(U,$J,358.3,3161,1,8,0)
 ;;=8^Chr Monocytic Leuk in Relapse
 ;;^UTILITY(U,$J,358.3,3161,2)
 ;;=^336477
 ;;^UTILITY(U,$J,358.3,3162,0)
 ;;=206.20^^29^257^55
 ;;^UTILITY(U,$J,358.3,3162,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,3162,1,1,0)
 ;;=1^206.20
 ;;^UTILITY(U,$J,358.3,3162,1,8,0)
 ;;=8^Subacute Monocytic Leuk w/o Remiss
 ;;^UTILITY(U,$J,358.3,3162,2)
 ;;=^336863
 ;;^UTILITY(U,$J,358.3,3163,0)
 ;;=206.21^^29^257^54
 ;;^UTILITY(U,$J,358.3,3163,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,3163,1,1,0)
 ;;=1^206.21
 ;;^UTILITY(U,$J,358.3,3163,1,8,0)
 ;;=8^Subacute Monocytic Leuk in Relapse
 ;;^UTILITY(U,$J,358.3,3163,2)
 ;;=^267548
 ;;^UTILITY(U,$J,358.3,3164,0)
 ;;=206.22^^29^257^56
 ;;^UTILITY(U,$J,358.3,3164,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,3164,1,1,0)
 ;;=1^206.22
 ;;^UTILITY(U,$J,358.3,3164,1,8,0)
 ;;=8^Subacute Monocytic Leuk w/o Remiss
 ;;^UTILITY(U,$J,358.3,3164,2)
 ;;=^336478
 ;;^UTILITY(U,$J,358.3,3165,0)
 ;;=206.80^^29^257^41
 ;;^UTILITY(U,$J,358.3,3165,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,3165,1,1,0)
 ;;=1^206.80
 ;;^UTILITY(U,$J,358.3,3165,1,8,0)
 ;;=8^Oth Monocytic Leuk w/ Remission
 ;;^UTILITY(U,$J,358.3,3165,2)
 ;;=^336864
 ;;^UTILITY(U,$J,358.3,3166,0)
 ;;=206.81^^29^257^40
 ;;^UTILITY(U,$J,358.3,3166,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,3166,1,1,0)
 ;;=1^206.81
 ;;^UTILITY(U,$J,358.3,3166,1,8,0)
 ;;=8^Oth Monocytic Leuk w/ Remiss
 ;;^UTILITY(U,$J,358.3,3166,2)
 ;;=^267551
 ;;^UTILITY(U,$J,358.3,3167,0)
 ;;=206.82^^29^257^39
 ;;^UTILITY(U,$J,358.3,3167,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,3167,1,1,0)
 ;;=1^206.82
 ;;^UTILITY(U,$J,358.3,3167,1,8,0)
 ;;=8^Oth Monocytic Leuk in Relapse
 ;;^UTILITY(U,$J,358.3,3167,2)
 ;;=^336479
 ;;^UTILITY(U,$J,358.3,3168,0)
 ;;=206.90^^29^257^62
 ;;^UTILITY(U,$J,358.3,3168,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,3168,1,1,0)
 ;;=1^206.90
 ;;^UTILITY(U,$J,358.3,3168,1,8,0)
 ;;=8^Unspec Monocytic Leuk w/o Remiss
 ;;^UTILITY(U,$J,358.3,3168,2)
 ;;=^336865
 ;;^UTILITY(U,$J,358.3,3169,0)
 ;;=206.91^^29^257^61
 ;;^UTILITY(U,$J,358.3,3169,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,3169,1,1,0)
 ;;=1^206.91
 ;;^UTILITY(U,$J,358.3,3169,1,8,0)
 ;;=8^Unspec Monocytic Leuk in Remiss
 ;;^UTILITY(U,$J,358.3,3169,2)
 ;;=^267554
 ;;^UTILITY(U,$J,358.3,3170,0)
 ;;=206.92^^29^257^60
 ;;^UTILITY(U,$J,358.3,3170,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,3170,1,1,0)
 ;;=1^206.92
 ;;^UTILITY(U,$J,358.3,3170,1,8,0)
 ;;=8^Unspec Monocytic Leuk in Relapse
